Cancer targeted therapeutics: From molecules to drug delivery vehicles

Journal of Controlled Release

Volumn 219, Issue , 2015, Pages 632-643

  Liu, Daxing ^a   Auguste, Debra T ^a  

^a City College of New York   (United States)

Author keywords

Active targeting; Integrated targeting; Passive targeting; Pharmacologic targeting; Targeted drug delivery

Indexed keywords

AMPHIBIOUS VEHICLES; CELL MEMBRANES; CHEMOTHERAPY; CYTOLOGY; DRUG THERAPY; SURFACE CHEMISTRY; TUMORS;

ACTIVE TARGETING; INTEGRATED TARGETING; PASSIVE TARGETING; PHARMACOLOGIC TARGETING; TARGETED DRUG DELIVERY;

DISEASES;

ANTINEOPLASTIC AGENT;

ARTICLE; DISTANT METASTASIS; DRUG DELIVERY SYSTEM; DRUG PENETRATION; DRUG RETENTION; DRUG TARGETING; HUMAN; MOLECULARLY TARGETED THERAPY; PARTICLE SIZE; PRIORITY JOURNAL; SURFACE PROPERTY; SYSTEMIC THERAPY; ANIMAL; NEOPLASMS;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; HUMANS; NEOPLASMS;

EID: 84947490389     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2015.08.041     Document Type: Article

References (185)

1. A. Gilman, and F.S. Philips The biological actions and therapeutic applications of the B-chloroethyl amines and sulfides Science 103 1946 409 436
2. L. Galluzzi, L. Senovilla, L. Zitvogel, and G. Kroemer The secret ally: immunostimulation by anticancer drugs Nat. Rev. Drug Discov. 11 2012 215 233
3. C. Sawyers Targeted cancer therapy Nature 432 2004 294 297
4. A. Gilman The initial clinical trial of nitrogen mustard Am. J. Surg. 105 1963 574 578
5. C. Heidelberger, N.K. Chaudhuri, P. Danneberg, D. Mooren, L. Griesbach, R. Duschinsky, R.J. Schnitzer, E. Pleven, and J. Scheiner Fluorinated pyrimidines, a new class of tumour-inhibitory compounds Nature 179 1957 663 666
6. M. Marty, F. Cognetti, D. Maraninchi, R. Snyder, L. Mauriac, M. Tubiana-Hulin, S. Chan, D. Grimes, A. Anton, A. Lluch, J. Kennedy, K. O'Byrne, P. Conte, M. Green, C. Ward, K. Mayne, and J.M. Extra Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group J. Clin. Oncol. 23 2005 4265 4274
7. M.D. Pegram, A. Lipton, D.F. Hayes, B.L. Weber, J.M. Baselga, D. Tripathy, D. Baly, S.A. Baughman, T. Twaddell, J.A. Glaspy, and D.J. Slamon Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment J. Clin. Oncol. 16 1998 2659 2671
8. R.L. Momparler, M. Karon, S.E. Siegel, and F. Avila Effect of adriamycin on DNA, RNA, and protein synthesis in cell-free systems and intact cells Cancer Res. 36 1976 2891 2895
9. C. Canel, R.M. Moraes, F.E. Dayan, and D. Ferreira Podophyllotoxin Phytochemistry 54 2000 115 120
10. B.L. Staker, K. Hjerrild, M.D. Feese, C.A. Behnke, A.B. Burgin Jr., and L. Stewart The mechanism of topoisomerase I poisoning by a camptothecin analog Proc. Natl. Acad. Sci. U. S. A. 99 2002 15387 15392
11. X. Zhao, H. Li, and R.J. Lee Targeted drug delivery via folate receptors Expert Opin. Drug Deliv. 5 2008 309 319
12. E. Bustamante, and P.L. Pedersen High aerobic glycolysis of rat hepatoma cells in culture: role of mitochondrial hexokinase Proc. Natl. Acad. Sci. U. S. A. 74 1977 3735 3739
13. R. Capdeville, E. Buchdunger, J. Zimmermann, and A. Matter Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug Nat. Rev. Drug Discov. 1 2002 493 502
14. B. Fisher, J.P. Costantino, D.L. Wickerham, C.K. Redmond, M. Kavanah, W.M. Cronin, V. Vogel, A. Robidoux, N. Dimitrov, J. Atkins, M. Daly, S. Wieand, E. Tan-Chiu, L. Ford, and N. Wolmark Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study J. Natl. Cancer Inst. 90 1998 1371 1388
15. M.E. O'Brien, N. Wigler, M. Inbar, R. Rosso, E. Grischke, A. Santoro, R. Catane, D.G. Kieback, P. Tomczak, S.P. Ackland, F. Orlandi, L. Mellars, L. Alland, C. Tendler, and C.B.C.S. Group Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer Ann. Oncol. 15 2004 440 449
16. A.H. Sarris, F. Hagemeister, J. Romaguera, M.A. Rodriguez, P. McLaughlin, A.M. Tsimberidou, L.J. Medeiros, B. Samuels, O. Pate, M. Oholendt, H. Kantarjian, C. Burge, and F. Cabanillas Liposomal vincristine in relapsed non-Hodgkin's lymphomas: early results of an ongoing phase II trial Ann. Oncol. 11 2000 69 72
17. S.C. White, P. Lorigan, G.P. Margison, J.M. Margison, F. Martin, N. Thatcher, H. Anderson, and M. Ranson Phase II study of SPI-77 (sterically stabilised liposomal cisplatin) in advanced non-small-cell lung cancer Br. J. Cancer 95 2006 822 828
18. J.O. Radler, I. Koltover, T. Salditt, and C.R. Safinya Structure of DNA-cationic liposome complexes: DNA intercalation in multilamellar membranes in distinct interhelical packing regimes Science 275 1997 810 814
19. J. Pei, C. Zhang, P.C. Gokhale, A. Rahman, A. Dritschilo, I. Ahmad, and U.N. Kasid Combination with liposome-entrapped, ends-modified raf antisense oligonucleotide (LErafAON) improves the anti-tumor efficacies of cisplatin, epirubicin, mitoxantrone, docetaxel and gemcitabine Anti-Cancer Drugs 15 2004 243 253
20. T. Konno, H. Maeda, K. Iwai, S. Tashiro, S. Maki, T. Morinaga, M. Mochinaga, T. Hiraoka, and I. Yokoyama Effect of arterial administration of high-molecular-weight anticancer agent SMANCS with lipid lymphographic agent on hepatoma: a preliminary report Eur. J. Cancer Clin. Oncol. 19 1983 1053 1065
21. H. Maeda, J. Wu, T. Sawa, Y. Matsumura, and K. Hori Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review J. Control. Release 65 2000 271 284
22. S. Danhauser-Riedl, E. Hausmann, H.D. Schick, R. Bender, H. Dietzfelbinger, J. Rastetter, and A.R. Hanauske Phase I clinical and pharmacokinetic trial of dextran conjugated doxorubicin (AD-70, DOX-OXD) Investig. New Drugs 11 1993 187 195
23. P.J. Julyan, L.W. Seymour, D.R. Ferry, S. Daryani, C.M. Boivin, J. Doran, M. David, D. Anderson, C. Christodoulou, A.M. Young, S. Hesslewood, and D.J. Kerr Preliminary clinical study of the distribution of HPMA copolymers bearing doxorubicin and galactosamine J. Control. Release 57 1999 281 290
24. J.W. Singer, B. Baker, P. De Vries, A. Kumar, S. Shaffer, E. Vawter, M. Bolton, and P. Garzone Poly-(l)-glutamic acid-paclitaxel (CT-2103) [XYOTAX], a biodegradable polymeric drug conjugate: characterization, preclinical pharmacology, and preliminary clinical data Adv. Exp. Med. Biol. 519 2003 81 99
25. W.J. Gradishar Albumin-bound paclitaxel: a next-generation taxane Expert. Opin. Pharmacother. 7 2006 1041 1053
26. A.N. Vis, A. van der Gaast, B.W. van Rhijn, T.K. Catsburg, C. Schmidt, and G.H. Mickisch A phase II trial of methotrexate-human serum albumin (MTX-HSA) in patients with metastatic renal cell carcinoma who progressed under immunotherapy Cancer Chemother. Pharmacol. 49 2002 342 345
27. T.Y. Kim, D.W. Kim, J.Y. Chung, S.G. Shin, S.C. Kim, D.S. Heo, N.K. Kim, and Y.J. Bang Phase I and pharmacokinetic study of Genexol-PM, a Cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies Clin. Cancer Res. 10 2004 3708 3716
28. J.A. Zhang, T. Xuan, M. Parmar, L. Ma, S. Ugwu, S. Ali, and I. Ahmad Development and characterization of a novel liposome-based formulation of SN-38 Int. J. Pharm. 270 2004 93 107
29. D.G. Maloney, A.J. Grillo-Lopez, C.A. White, D. Bodkin, R.J. Schilder, J.A. Neidhart, N. Janakiraman, K.A. Foon, T.M. Liles, B.K. Dallaire, K. Wey, I. Royston, T. Davis, and R. Levy IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma Blood 90 1997 2188 2195
30. D.J. Slamon, G.M. Clark, S.G. Wong, W.J. Levin, A. Ullrich, and W.L. McGuire Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene Science 235 1987 177 182
31. J.C. Edwards, L. Szczepanski, J. Szechinski, A. Filipowicz-Sosnowska, P. Emery, D.R. Close, R.M. Stevens, and T. Shaw Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis N. Engl. J. Med. 350 2004 2572 2581
32. H.S. Friedman, M.D. Prados, P.Y. Wen, T. Mikkelsen, D. Schiff, L.E. Abrey, W.K. Yung, N. Paleologos, M.K. Nicholas, R. Jensen, J. Vredenburgh, J. Huang, M. Zheng, and T. Cloughesy Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma J. Clin. Oncol. 27 2009 4733 4740
33. W.A. Messersmith, and D.J. Ahnen Targeting EGFR in colorectal cancer N. Engl. J. Med. 359 2008 1834 1836
34. M.M. Heiss, P. Murawa, P. Koralewski, E. Kutarska, O.O. Kolesnik, V.V. Ivanchenko, A.S. Dudnichenko, B. Aleknaviciene, A. Razbadauskas, M. Gore, E. Ganea-Motan, T. Ciuleanu, P. Wimberger, A. Schmittel, B. Schmalfeldt, A. Burges, C. Bokemeyer, H. Lindhofer, A. Lahr, and S.L. Parsons The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II/III trial Int. J. Cancer 127 2010 2209 2221
35. W.K. Boland, and G. Bebb Nimotuzumab: a novel anti-EGFR monoclonal antibody that retains anti-EGFR activity while minimizing skin toxicity Expert. Opin. Biol. Ther. 9 2009 1199 1206
36. D.R. Leach, M.F. Krummel, and J.P. Allison Enhancement of antitumor immunity by CTLA-4 blockade Science 271 1996 1734 1736
37. C. Sheridan Pertuzumab to bolster Roche/Genentech's breast cancer franchise? Nat. Biotechnol. 29 2011 856 858
38. D.G. Sheer, J. Schlom, and H.L. Cooper Purification and composition of the human tumor-associated glycoprotein (TAG-72) defined by monoclonal antibodies CC49 and B72.3 Cancer Res. 48 1988 6811 6818
39. E. Ruoslahti Specialization of tumour vasculature Nat. Rev. Cancer 2 2002 83 90
40. M. Duvic, T.M. Kuzel, E.A. Olsen, A.G. Martin, F.M. Foss, Y.H. Kim, P.W. Heald, P. Bacha, J. Nichols, and A. Liepa Quality-of-life improvements in cutaneous T-cell lymphoma patients treated with denileukin diftitox (ONTAK) Clin. Lymphoma 2 2002 222 228
41. P.F. Bross, J. Beitz, G. Chen, X.H. Chen, E. Duffy, L. Kieffer, S. Roy, R. Sridhara, A. Rahman, G. Williams, and R. Pazdur Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia Clin. Cancer Res. 7 2001 1490 1496
42. D.E. Milenic, E.D. Brady, and M.W. Brechbiel Antibody-targeted radiation cancer therapy Nat. Rev. Drug Discov. 3 2004 488 499
43. B.D. Cheson, and J.P. Leonard Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma N. Engl. J. Med. 359 2008 613 626
44. B. Hughes Antibody-drug conjugates for cancer: poised to deliver? Nat. Rev. Drug Discov. 9 2010 665 667
45. S. Verma, D. Miles, L. Gianni, I.E. Krop, M. Welslau, J. Baselga, M. Pegram, D.Y. Oh, V. Dieras, E. Guardino, L. Fang, M.W. Lu, S. Olsen, K. Blackwell, and E.S. Group Trastuzumab emtansine for HER2-positive advanced breast cancer N. Engl. J. Med. 367 2012 1783 1791
46. S. Chen, L. Yu, C. Jiang, Y. Zhao, D. Sun, S. Li, G. Liao, Y. Chen, Q. Fu, Q. Tao, D. Ye, P. Hu, L.A. Khawli, C.R. Taylor, A.L. Epstein, and D.W. Ju Pivotal study of iodine-131-labeled chimeric tumor necrosis treatment radioimmunotherapy in patients with advanced lung cancer J. Clin. Oncol. 23 2005 1538 1547
47. P. Attia, A.V. Maker, L.R. Haworth, L. Rogers-Freezer, and S.A. Rosenberg Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma J. Immunother. 28 2005 582 592
48. S. Sengupta, D. Eavarone, I. Capila, G. Zhao, N. Watson, T. Kiziltepe, and R. Sasisekharan Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system Nature 436 2005 568 572
49. A. Dicko, L.D. Mayer, and P.G. Tardi Use of nanoscale delivery systems to maintain synergistic drug ratios in vivo Expert Opin. Drug Deliv. 7 2010 1329 1341
50. A. Mohamed, X. Deng, F.R. Khuri, and T.K. Owonikoko Altered glutamine metabolism and therapeutic opportunities for lung cancer Clin. Lung Cancer 15 2014 7 15
51. V. Sanna, and M. Sechi Nanoparticle therapeutics for prostate cancer treatment Maturitas 73 2012 27 32
52. R.J. Amato, A. Shetty, Y. Lu, R. Ellis, and P.S. Low A phase I study of folate immune therapy (EC90 vaccine administered with GPI-0100 adjuvant followed by EC17) in patients with renal cell carcinoma J. Immunother. 36 2013 268 275
53. S.S. Dharap, B. Qiu, G.C. Williams, P. Sinko, S. Stein, and T. Minko Molecular targeting of drug delivery systems to ovarian cancer by BH3 and LHRH peptides J. Control. Release 91 2003 61 73
54. A.T. Stopeck, A. Jones, E.M. Hersh, J.A. Thompson, D.M. Finucane, J.C. Gutheil, and R. Gonzalez Phase II study of direct intralesional gene transfer of allovectin-7, an HLA-B7/beta2-microglobulin DNA-liposome complex, in patients with metastatic melanoma Clin. Cancer Res. 7 2001 2285 2291
55. V.P. Torchilin Recent advances with liposomes as pharmaceutical carriers Nat. Rev. Drug Discov. 4 2005 145 160
56. T. Kakudo, S. Chaki, S. Futaki, I. Nakase, K. Akaji, T. Kawakami, K. Maruyama, H. Kamiya, and H. Harashima Transferrin-modified liposomes equipped with a pH-sensitive fusogenic peptide: an artificial viral-like delivery system Biochemistry 43 2004 5618 5628
57. Y. Matsumura, M. Gotoh, K. Muro, Y. Yamada, K. Shirao, Y. Shimada, M. Okuwa, S. Matsumoto, Y. Miyata, H. Ohkura, K. Chin, S. Baba, T. Yamao, A. Kannami, Y. Takamatsu, K. Ito, and K. Takahashi Phase I and pharmacokinetic study of MCC-465, a doxorubicin (DXR) encapsulated in PEG immunoliposome, in patients with metastatic stomach cancer Ann. Oncol. 15 2004 517 525
58. E. Fernandes, J.A. Ferreira, P. Andreia, L. Luis, S. Barroso, B. Sarmento, and L.L. Santos New trends in guided nanotherapies for digestive cancers: a systematic review J. Control. Release 209 2015 288 307
59. N. Senzer, J. Nemunaitis, D. Nemunaitis, C. Bedell, G. Edelman, M. Barve, R. Nunan, K.F. Pirollo, A. Rait, and E.H. Chang Phase I study of a systemically delivered p53 nanoparticle in advanced solid tumors Mol. Ther. 21 2013 1096 1103
60. J.E. Zuckerman, I. Gritli, A. Tolcher, J.D. Heidel, D. Lim, R. Morgan, B. Chmielowski, A. Ribas, M.E. Davis, and Y. Yen Correlating animal and human phase Ia/Ib clinical data with CALAA-01, a targeted, polymer-based nanoparticle containing siRNA Proc. Natl. Acad. Sci. U. S. A. 111 2014 11449 11454
61. D.R. Miller A tribute to Sidney Farber - the father of modern chemotherapy Br. J. Haematol. 134 2006 20 26
62. T. Schindler, W. Bornmann, P. Pellicena, W.T. Miller, B. Clarkson, and J. Kuriyan Structural mechanism for STI-571 inhibition of abelson tyrosine kinase Science 289 2000 1938 1942
63. V.P. Chauhan, T. Stylianopoulos, Y. Boucher, and R.K. Jain Delivery of molecular and nanoscale medicine to tumors: transport barriers and strategies Annu. Rev. Chem. Biomol. Eng. 2 2011 281 298
64. M. Suzuki, K. Hori, I. Abe, S. Saito, and H. Sato A new approach to cancer chemotherapy: selective enhancement of tumor blood flow with angiotensin II J. Natl. Cancer Inst. 67 1981 663 669
65. H. Maeda, T. Matsumoto, T. Konno, K. Iwai, and M. Ueda Tailor-making of protein drugs by polymer conjugation for tumor targeting - a brief review on smancs J. Protein Chem. 3 1984 181 193
66. Y. Matsumura, and H. Maeda A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs Cancer Res. 46 1986 6387 6392
67. L.E. Gerlowski, and R.K. Jain Microvascular permeability of normal and neoplastic tissues Microvasc. Res. 31 1986 288 305
68. T.M. Allen, and P.R. Cullis Drug delivery systems: entering the mainstream Science 303 2004 1818 1822
69. G.T. Noble, J.F. Stefanick, J.D. Ashley, T. Kiziltepe, and B. Bilgicer Ligand-targeted liposome design: challenges and fundamental considerations Trends Biotechnol. 32 2014 32 45
70. E. Wisse, F. Jacobs, B. Topal, P. Frederik, and B. De Geest The size of endothelial fenestrae in human liver sinusoids: implications for hepatocyte-directed gene transfer Gene Ther. 15 2008 1193 1199
71. W.M. Deen, M.J. Lazzara, and B.D. Myers Structural determinants of glomerular permeability Am. J. Physiol. Am. J. Physiol. Renal Physiol. 281 2001 F579 F596
72. H.S. Choi, W. Liu, P. Misra, E. Tanaka, J.P. Zimmer, B. Itty Ipe, M.G. Bawendi, and J.V. Frangioni Renal clearance of quantum dots Nat. Biotechnol. 25 2007 1165 1170
73. M. Gaumet, A. Vargas, R. Gurny, and F. Delie Nanoparticles for drug delivery: the need for precision in reporting particle size parameters J. Pharmacokinet. Biopharm. 69 2008 1 9
74. R. Duncan, M.J. Vicent, F. Greco, and R.I. Nicholson Polymer-drug conjugates: towards a novel approach for the treatment of endocrine-related cancer Endocr. Relat. Cancer 12 Suppl 1 2005 S189 S199
75. 2 Ann. Oncol. 11 2000 1029 1033
76. P.Y. Muller, and M.N. Milton The determination and interpretation of the therapeutic index in drug development Nat. Rev. Drug Discov. 11 2012 751 761
77. S. Jain, D.G. Hirst, and J.M. O'Sullivan Gold nanoparticles as novel agents for cancer therapy Br. J. Radiol. 85 2012 101 113
78. A.M. Smith, H. Duan, A.M. Mohs, and S. Nie Bioconjugated quantum dots for in vivo molecular and cellular imaging Adv. Drug Deliv. Rev. 60 2008 1226 1240
79. Z. Li, J.C. Barnes, A. Bosoy, J.F. Stoddart, and J.I. Zink Mesoporous silica nanoparticles in biomedical applications Chem. Soc. Rev. 41 2012 2590 2605
80. B. Chertok, B.A. Moffat, A.E. David, F. Yu, C. Bergemann, B.D. Ross, and V.C. Yang Iron oxide nanoparticles as a drug delivery vehicle for MRI monitored magnetic targeting of brain tumors Biomaterials 29 2008 487 496
81. Z. Liu, K. Chen, C. Davis, S. Sherlock, Q. Cao, X. Chen, and H. Dai Drug delivery with carbon nanotubes for in vivo cancer treatment Cancer Res. 68 2008 6652 6660
82. K. Yang, S. Zhang, G. Zhang, X. Sun, S.T. Lee, and Z. Liu Graphene in mice: ultrahigh in vivo tumor uptake and efficient photothermal therapy Nano Lett. 10 2010 3318 3323
83. E.K. Chow, X.Q. Zhang, M. Chen, R. Lam, E. Robinson, H. Huang, D. Schaffer, E. Osawa, A. Goga, and D. Ho Nanodiamond therapeutic delivery agents mediate enhanced chemoresistant tumor treatment Sci. Transl. Med. 3 2011 73ra21
84. K. Maruyama Intracellular targeting delivery of liposomal drugs to solid tumors based on EPR effects Adv. Drug Deliv. Rev. 63 2011 161 169
85. S. Ohno, M. Takanashi, K. Sudo, S. Ueda, A. Ishikawa, N. Matsuyama, K. Fujita, T. Mizutani, T. Ohgi, T. Ochiya, N. Gotoh, and M. Kuroda Systemically injected exosomes targeted to EGFR deliver antitumor microRNA to breast cancer cells Mol. Ther. 21 2013 185 191
86. H. Maeda, G.Y. Bharate, and J. Daruwalla Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect Eur. J. Pharm. Biopharm. 71 2009 409 419
87. A.K. Patri, J.F. Kukowska-Latallo, and J.R. Baker Jr. Targeted drug delivery with dendrimers: comparison of the release kinetics of covalently conjugated drug and non-covalent drug inclusion complex Adv. Drug Deliv. Rev. 57 2005 2203 2214
88. H. Kobayashi, R. Watanabe, and P.L. Choyke Improving conventional enhanced permeability and retention (EPR) effects; what is the appropriate target? Theranostics 4 2013 81 89
89. J.A. Hubbell, and R. Langer Translating materials design to the clinic Nat. Mater. 12 2013 963 966
90. S. Bisht, and A. Maitra Dextran-doxorubicin/chitosan nanoparticles for solid tumor therapy Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 1 2009 415 425
91. A. Lamprecht Nanomedicines in gastroenterology and hepatology Nat. Rev. Gastroenterol. Hepatol. 12 2015 195 204
92. S. Mitragotri, and J. Lahann Physical approaches to biomaterial design Nat. Mater. 8 2009 15 23
93. N. Bertrand, J. Wu, X. Xu, N. Kamaly, and O.C. Farokhzad Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology Adv. Drug Deliv. Rev. 66 2014 2 25
94. F. Yuan, M. Dellian, D. Fukumura, M. Leunig, D.A. Berk, V.P. Torchilin, and R.K. Jain Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size Cancer Res. 55 1995 3752 3756
95. M.R. Dreher, W. Liu, C.R. Michelich, M.W. Dewhirst, F. Yuan, and A. Chilkoti Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers J. Natl. Cancer Inst. 98 2006 335 344
96. A. Pluen, Y. Boucher, S. Ramanujan, T.D. McKee, T. Gohongi, E. di Tomaso, E.B. Brown, Y. Izumi, R.B. Campbell, D.A. Berk, and R.K. Jain Role of tumor-host interactions in interstitial diffusion of macromolecules: cranial vs. subcutaneous tumors Proc. Natl. Acad. Sci. U. S. A. 98 2001 4628 4633
97. I. Canton, and G. Battaglia Endocytosis at the nanoscale Chem. Soc. Rev. 41 2012 2718 2739
98. F. Danhier, O. Feron, and V. Preat To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery J. Control. Release 148 2010 135 146
99. C. He, Y. Hu, L. Yin, C. Tang, and C. Yin Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles Biomaterials 31 2010 3657 3666
100. S. Jiang, and Z. Cao Ultralow-fouling, functionalizable, and hydrolyzable zwitterionic materials and their derivatives for biological applications Adv. Mater. 22 2010 920 932
101. M.T. Peracchia, E. Fattal, D. Desmaele, M. Besnard, J.P. Noel, J.M. Gomis, M. Appel, J. d'Angelo, and P. Couvreur Stealth PEGylated polycyanoacrylate nanoparticles for intravenous administration and splenic targeting J. Control. Release 60 1999 121 128
102. R.B. Campbell, D. Fukumura, E.B. Brown, L.M. Mazzola, Y. Izumi, R.K. Jain, V.P. Torchilin, and L.L. Munn Cationic charge determines the distribution of liposomes between the vascular and extravascular compartments of tumors Cancer Res. 62 2002 6831 6836
103. J.M. Lohr, S.L. Haas, W.O. Bechstein, G. Bodoky, K. Cwiertka, W. Fischbach, U.R. Folsch, D. Jager, D. Osinsky, J. Prausova, W.E. Schmidt, M.P. Lutz, and C.T.S. Group Cationic liposomal paclitaxel plus gemcitabine or gemcitabine alone in patients with advanced pancreatic cancer: a randomized controlled phase II trial Ann. Oncol. 23 2012 1214 1222
104. O. Lieleg, R.M. Baumgartel, and A.R. Bausch Selective filtering of particles by the extracellular matrix: an electrostatic bandpass Biophys. J. 97 2009 1569 1577
105. P. Xu, E.A. Van Kirk, Y. Zhan, W.J. Murdoch, M. Radosz, and Y. Shen Targeted charge-reversal nanoparticles for nuclear drug delivery Angew. Chem. Int. Ed. Engl. 46 2007 4999 5002
106. J.A. Champion, and S. Mitragotri Role of target geometry in phagocytosis Proc. Natl. Acad. Sci. U. S. A. 103 2006 4930 4934
107. J.A. Champion, Y.K. Katare, and S. Mitragotri Particle shape: a new design parameter for micro- and nanoscale drug delivery carriers J. Control. Release 121 2007 3 9
108. V.P. Chauhan, Z. Popovic, O. Chen, J. Cui, D. Fukumura, M.G. Bawendi, and R.K. Jain Fluorescent nanorods and nanospheres for real-time in vivo probing of nanoparticle shape-dependent tumor penetration Angew. Chem. Int. Ed. Engl. 50 2011 11417 11420
109. S.E. Gratton, P.A. Ropp, P.D. Pohlhaus, J.C. Luft, V.J. Madden, M.E. Napier, and J.M. DeSimone The effect of particle design on cellular internalization pathways Proc. Natl. Acad. Sci. U. S. A. 105 2008 11613 11618
110. 198Au-doped nanostructures with different shapes for in vivo analyses of their biodistribution, tumor uptake, and intratumoral distribution ACS Nano 8 2014 4385 4394
111. B.R. Smith, P. Kempen, D. Bouley, A. Xu, Z. Liu, N. Melosh, H. Dai, R. Sinclair, and S.S. Gambhir Shape matters: intravital microscopy reveals surprising geometrical dependence for nanoparticles in tumor models of extravasation Nano Lett. 12 2012 3369 3377
112. C. Picart, and D.E. Discher Materials science: embedded shells decalcified Nature 448 2007 879 880
113. C.C. Lee, J.A. MacKay, J.M. Frechet, and F.C. Szoka Designing dendrimers for biological applications Nat. Biotechnol. 23 2005 1517 1526
114. D. Peer, J.M. Karp, S. Hong, O.C. Farokhzad, R. Margalit, and R. Langer Nanocarriers as an emerging platform for cancer therapy Nat. Biotechnol. 2 2007 751 760
115. A.H. Ko, M.A. Tempero, Y.S. Shan, W.C. Su, Y.L. Lin, E. Dito, A. Ong, Y.W. Wang, C.G. Yeh, and L.T. Chen A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer Br. J. Cancer 109 2013 920 925
116. D.D. Von Hoff, T. Ervin, F.P. Arena, E.G. Chiorean, J. Infante, M. Moore, T. Seay, S.A. Tjulandin, W.W. Ma, M.N. Saleh, M. Harris, M. Reni, S. Dowden, D. Laheru, N. Bahary, R.K. Ramanathan, J. Tabernero, M. Hidalgo, D. Goldstein, E. Van Cutsem, X. Wei, J. Iglesias, and M.F. Renschler Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine N. Engl. J. Med. 369 2013 1691 1703
117. P.A. Vasey, S.B. Kaye, R. Morrison, C. Twelves, P. Wilson, R. Duncan, A.H. Thomson, L.S. Murray, T.E. Hilditch, T. Murray, S. Burtles, D. Fraier, E. Frigerio, and J. Cassidy Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee Clin. Cancer Res. 5 1999 83 94
118. K. Strebhardt, and A. Ullrich Paul Ehrlich's magic bullet concept: 100 years of progress Nat. Rev. Cancer 8 2008 473 480
119. L. Pauling, and M. Delbruck The nature of the intermolecular forces operative in biological processes Science 92 1940 77 79
120. G. Kohler, and C. Milstein Continuous cultures of fused cells secreting antibody of predefined specificity Nature 256 1975 495 497
121. R.A. Miller, D.G. Maloney, R. Warnke, and R. Levy Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody N. Engl. J. Med. 306 1982 517 522
122. A.J. Grillo-Lopez, C.A. White, C. Varns, D. Shen, A. Wei, A. McClure, and B.K. Dallaire Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma Semin. Oncol. 26 1999 66 73
123. C.A. Hudis Trastuzumab - mechanism of action and use in clinical practice N. Engl. J. Med. 357 2007 39 51
124. T. Ghose, S.T. Norvell, A. Guclu, D. Cameron, A. Bodurtha, and A.S. MacDonald Immunochemotherapy of cancer with chlorambucil-carrying antibody Br. Med. J. 3 1972 495 499
125. I. Flechner The cure and concomitant immunization of mice bearing Ehrlich ascites tumors by treatment with an antibody-alkylating agent complex Eur. J. Cancer 9 1973 741 745
126. D.A. Davies, and G.J. O'Neill In vivo and in vitro effects of tumour specific antibodies with chlorambucil Br. J. Cancer Suppl. 1 1973 285 298
127. E. Hurwitz, R. Levy, R. Maron, M. Wilchek, R. Arnon, and M. Sela The covalent binding of daunomycin and adriamycin to antibodies, with retention of both drug and antibody activities Cancer Res. 35 1975 1175 1181
128. D.W. Bartlett, H. Su, I.J. Hildebrandt, W.A. Weber, and M.E. Davis Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging Proc. Natl. Acad. Sci. U. S. A. 104 2007 15549 15554
129. D.B. Kirpotin, D.C. Drummond, Y. Shao, M.R. Shalaby, K. Hong, U.B. Nielsen, J.D. Marks, C.C. Benz, and J.W. Park Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models Cancer Res. 66 2006 6732 6740
130. D.T. Wiley, P. Webster, A. Gale, and M.E. Davis Transcytosis and brain uptake of transferrin-containing nanoparticles by tuning avidity to transferrin receptor Proc. Natl. Acad. Sci. U. S. A. 110 2013 8662 8667
131. J.N. Weinstein, and W. van Osdol Early intervention in cancer using monoclonal antibodies and other biological ligands: micropharmacology and the "binding site barrier" Cancer Res. 52 1992 2747s 2751s
132. M.M. Schmidt, and K.D. Wittrup A modeling analysis of the effects of molecular size and binding affinity on tumor targeting Mol. Cancer Ther. 8 2009 2861 2871
133. Z. Hu, Y. Sun, and A. Garen Targeting tumor vasculature endothelial cells and tumor cells for immunotherapy of human melanoma in a mouse xenograft model Proc. Natl. Acad. Sci. U. S. A. 96 1999 8161 8166
134. M. Loeffler, J.A. Kruger, A.G. Niethammer, and R.A. Reisfeld Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake J. Clin. Invest. 116 2006 1955 1962
135. R. Opavsky, P. Haviernik, D. Jurkovicova, M.T. Garin, N.G. Copeland, D.J. Gilbert, N.A. Jenkins, J. Bies, S. Garfield, S. Pastorekova, A. Oue, and L. Wolff Molecular characterization of the mouse Tem1/endosialin gene regulated by cell density in vitro and expressed in normal tissues in vivo J. Biol. Chem. 276 2001 38795 38807
136. R.O. Schlingemann, E. Oosterwijk, P. Wesseling, F.J. Rietveld, and D.J. Ruiter Aminopeptidase a is a constituent of activated pericytes in angiogenesis J. Pathol. 179 1996 436 442
137. O. Barreiro, M. Yanez-Mo, J.M. Serrador, M.C. Montoya, M. Vicente-Manzanares, R. Tejedor, H. Furthmayr, and F. Sanchez-Madrid Dynamic interaction of VCAM-1 and ICAM-1 with moesin and ezrin in a novel endothelial docking structure for adherent leukocytes J. Cell Biol. 157 2002 1233 1245
138. W. Arap, R. Pasqualini, and E. Ruoslahti Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model Science 279 1998 377 380
139. F. Curnis, G. Arrigoni, A. Sacchi, L. Fischetti, W. Arap, R. Pasqualini, and A. Corti Differential binding of drugs containing the NGR motif to CD13 isoforms in tumor vessels, epithelia, and myeloid cells Cancer Res. 62 2002 867 874
140. T. Reissmann, A.V. Schally, P. Bouchard, H. Riethmiiller, and J. Engel The LHRH antagonist cetrorelix: a review Hum. Reprod. Update 6 2000 322 331
141. A.D. Ellington, and J.W. Szostak In vitro selection of RNA molecules that bind specific ligands Nature 346 1990 818 822
142. C. Tuerk, and L. Gold Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase Science 249 1990 505 510
143. L. Cerchia, and V. de Franciscis Targeting cancer cells with nucleic acid aptamers Trends Biotechnol. 28 2010 517 525
144. A.E. Smith, and A. Helenius How viruses enter animal cells Science 304 2004 237 242
145. M.J. Endres, P.R. Clapham, M. Marsh, M. Ahuja, J.D. Turner, A. McKnight, J.F. Thomas, B. Stoebenau-Haggarty, S. Choe, P.J. Vance, T.N. Wells, C.A. Power, S.S. Sutterwala, R.W. Doms, N.R. Landau, and J.A. Hoxie CD4-independent infection by HIV-2 is mediated by Fusin/CXCR4 Cell 87 1996 745 756
146. S. Chatterjee, P.R. Johnson, and K.K. Wong Jr. Dual-target inhibition of HIV-1 in vitro by means of an adeno-associated virus antisense vector Science 258 1992 1485 1488
147. M.K. Yu, J. Park, and S. Jon Targeting strategies for multifunctional nanoparticles in cancer imaging and therapy Theranostics 2 2012 3 44
148. N.E. Hynes, and H.A. Lane ERBB receptors and cancer: the complexity of targeted inhibitors Nat. Rev. Cancer 5 2005 341 354
149. M.J. Cudmore, P.W. Hewett, S. Ahmad, K.Q. Wang, M. Cai, B. Al-Ani, T. Fujisawa, B. Ma, S. Sissaoui, W. Ramma, M.R. Miller, D.E. Newby, Y. Gu, B. Barleon, H. Weich, and A. Ahmed The role of heterodimerization between VEGFR-1 and VEGFR-2 in the regulation of endothelial cell homeostasis Nat. Commun. 3 2012 972
150. J.S. Josan, H.L. Handl, R. Sankaranarayanan, L. Xu, R.M. Lynch, J. Vagner, E.A. Mash, V.J. Hruby, and R.J. Gillies Cell-specific targeting by heterobivalent ligands Bioconjug. Chem. 22 2011 1270 1278
151. L. Xu, J.S. Josan, J. Vagner, M.R. Caplan, V.J. Hruby, E.A. Mash, R.M. Lynch, D.L. Morse, and R.J. Gillies Heterobivalent ligands target cell-surface receptor combinations in vivo Proc. Natl. Acad. Sci. U. S. A. 109 2012 21295 21300
152. Y. Murase, T. Asai, Y. Katanasaka, T. Sugiyama, K. Shimizu, N. Maeda, and N. Oku A novel DDS strategy, "dual-targeting", and its application for antineovascular therapy Cancer Lett. 287 2010 165 171
153. F. Re, I. Cambianica, C. Zona, S. Sesana, M. Gregori, R. Rigolio, B. La Ferla, F. Nicotra, G. Forloni, A. Cagnotto, M. Salmona, M. Masserini, and G. Sancini Functionalization of liposomes with ApoE-derived peptides at different density affects cellular uptake and drug transport across a blood-brain barrier model Nanomedicine 7 2011 551 559
154. J.R. Junutula, H. Raab, S. Clark, S. Bhakta, D.D. Leipold, S. Weir, Y. Chen, M. Simpson, S.P. Tsai, M.S. Dennis, Y. Lu, Y.G. Meng, C. Ng, J. Yang, C.C. Lee, E. Duenas, J. Gorrell, V. Katta, A. Kim, K. McDorman, K. Flagella, R. Venook, S. Ross, S.D. Spencer, W. Lee Wong, H.B. Lowman, R. Vandlen, M.X. Sliwkowski, R.H. Scheller, P. Polakis, and W. Mallet Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index Nat. Biotechnol. 26 2008 925 932
155. J.Y. Axup, K.M. Bajjuri, M. Ritland, B.M. Hutchins, C.H. Kim, S.A. Kazane, R. Halder, J.S. Forsyth, A.F. Santidrian, K. Stafin, Y. Lu, H. Tran, A.J. Seller, S.L. Biroc, A. Szydlik, J.K. Pinkstaff, F. Tian, S.C. Sinha, B. Felding-Habermann, V.V. Smider, and P.G. Schultz Synthesis of site-specific antibody-drug conjugates using unnatural amino acids Proc. Natl. Acad. Sci. U. S. A. 109 2012 16101 16106
156. A.C. Parente-Pereira, H. Shmeeda, L.M. Whilding, C.P. Zambirinis, J. Foster, S.J. van der Stegen, R. Beatson, T. Zabinski, N. Brewig, J.K. Sosabowski, S. Mather, S. Ghaem-Maghami, A. Gabizon, and J. Maher Adoptive immunotherapy of epithelial ovarian cancer with Vgamma9Vdelta2 T cells, potentiated by liposomal alendronic acid J. Immunol. 193 2014 5557 5566
157. D.M. Wall, C.V. Srikanth, and B.A. McCormick Targeting tumors with salmonella Typhimurium - potential for therapy Oncotarget 1 2010 721 728
158. D. Akin, J. Sturgis, K. Ragheb, D. Sherman, K. Burkholder, J.P. Robinson, A.K. Bhunia, S. Mohammed, and R. Bashir Bacteria-mediated delivery of nanoparticles and cargo into cells Nat. Nanotechnol. 2 2007 441 449
159. S.A. Grupp, M. Kalos, D. Barrett, R. Aplenc, D.L. Porter, S.R. Rheingold, D.T. Teachey, A. Chew, B. Hauck, J.F. Wright, M.C. Milone, B.L. Levine, and C.H. June Chimeric antigen receptor-modified T cells for acute lymphoid leukemia N. Engl. J. Med. 368 2013 1509 1518
160. B. Huang, W.D. Abraham, Y. Zheng, S.C. Bustamante Lopez, S.S. Luo, and D.J. Irvine Active targeting of chemotherapy to disseminated tumors using nanoparticle-carrying T cells Sci. Transl. Med. 7 2015 291ra294
161. M.T. Stephan, J.J. Moon, S.H. Um, A. Bershteyn, and D.J. Irvine Therapeutic cell engineering with surface-conjugated synthetic nanoparticles Nat. Med. 16 2010 1035 1041
162. C.M. Southam, and A.E. Moore Clinical studies of viruses as antineoplastic agents with particular reference to Egypt 101 virus Cancer 5 1952 1025 1034
163. T.S. Miest, and R. Cattaneo New viruses for cancer therapy: meeting clinical needs Nat. Rev. Microbiol. 12 2014 23 34
164. J. Fueyo, C. Gomez-Manzano, R. Alemany, P.S. Lee, T.J. McDonnell, P. Mitlianga, Y.X. Shi, V.A. Levin, W.K. Yung, and A.P. Kyritsis A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo Oncogene 19 2000 2 12
165. C.K. Navaratnarajah, T.S. Miest, A. Carfi, and R. Cattaneo Targeted entry of enveloped viruses: measles and herpes simplex virus I Curr. Opin. Virol. 2 2012 43 49
166. C. Sheridan First oncolytic virus edges towards approval in surprise vote Nat. Biotechnol. 33 2015 569 570
167. V.P. Torchilin Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery Nat. Rev. Drug Discov. 13 2014 813 827
168. F. Scherer, M. Anton, U. Schillinger, J. Henke, C. Bergemann, A. Kruger, B. Gansbacher, and C. Plank Magnetofection: enhancing and targeting gene delivery by magnetic force in vitro and in vivo Gene Ther. 9 2002 102 109
169. G. Batist, K.A. Gelmon, K.N. Chi, W.H. Miller Jr., S.K. Chia, L.D. Mayer, C.E. Swenson, A.S. Janoff, and A.C. Louie Safety, pharmacokinetics, and efficacy of CPX-1 liposome injection in patients with advanced solid tumors Clin. Cancer Res. 15 2009 692 700
170. T. Danino, A. Prindle, G.A. Kwong, M. Skalak, H. Li, K. Allen, J. Hasty, and S.N. Bhatia Programmable probiotics for detection of cancer in urine Sci. Transl. Med. 7 2015 289ra284
171. T. Lammers, W.E. Hennink, and G. Storm Tumour-targeted nanomedicines: principles and practice Br. J. Cancer 99 2008 392 397
172. A. Kamb, S. Wee, and C. Lengauer Why is cancer drug discovery so difficult? Nat. Rev. Drug Discov. 6 2007 115 120
173. A. Beck, T. Wurch, C. Bailly, and N. Corvaia Strategies and challenges for the next generation of therapeutic antibodies Nat. Rev. Immunol. 10 2010 345 352
174. Y. Nagata, K.H. Lan, X. Zhou, M. Tan, F.J. Esteva, A.A. Sahin, K.S. Klos, P. Li, B.P. Monia, N.T. Nguyen, G.N. Hortobagyi, M.C. Hung, and D. Yu PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients Cancer Cell 6 2004 117 127
175. L.D. Leserman, J. Barbet, F. Kourilsky, and J.N. Weinstein Targeting to cells of fluorescent liposomes covalently coupled with monoclonal antibody or protein A Nature 288 1980 602 604
176. T.D. Heath, R.T. Fraley, and D. Papahdjopoulos Antibody targeting of liposomes: cell specificity obtained by conjugation of F(ab')2 to vesicle surface Science 210 1980 539 541
177. W.P. Fan, B. Shen, W.B. Bu, X.P. Zheng, Q.J. He, Z.W. Cui, K.L. Zhao, S.J. Zhang, and J.L. Shi Design of an intelligent sub-50 nm nuclear-targeting nanotheranostic system for imaging guided intranuclear radiosensitization Chem. Sci. 6 2015 1747 1753
178. N. Nasongkla, E. Bey, J. Ren, H. Ai, C. Khemtong, J.S. Guthi, S.F. Chin, A.D. Sherry, D.A. Boothman, and J. Gao Multifunctional polymeric micelles as cancer-targeted, MRI-ultrasensitive drug delivery systems Nano Lett. 6 2006 2427 2430
179. O. Warburg On the origin of cancer cells Science 123 1956 309 314
180. G.J. Kelloff, J.M. Hoffman, B. Johnson, H.I. Scher, B.A. Siegel, E.Y. Cheng, B.D. Cheson, J. O'Shaughnessy, K.Z. Guyton, D.A. Mankoff, L. Shankar, S.M. Larson, C.C. Sigman, R.L. Schilsky, and D.C. Sullivan Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development Clin. Cancer Res. 11 2005 2785 2808
181. X. Feng, P. Wang, Q. Liu, T. Zhang, B. Mai, and X. Wang Glycolytic inhibitors 2-deoxyglucose and 3-bromopyruvate synergize with photodynamic therapy respectively to inhibit cell migration J. Bioenerg. Biomembr. 47 2015 189 197
182. M.G. Vander Heiden Targeting cancer metabolism: a therapeutic window opens Nat. Rev. Drug Discov. 10 2011 671 684
183. R.K. Jain, and T. Stylianopoulos Delivering nanomedicine to solid tumors Nat. Rev. Clin. Oncol. 7 2010 653 664
184. P.P. Adiseshaiah, J.B. Hall, and S.E. McNeil Nanomaterial standards for efficacy and toxicity assessment Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 2 2010 99 112
185. W.J. Gradishar, D. Krasnojon, S. Cheporov, A.N. Makhson, G.M. Manikhas, A. Clawson, and P. Bhar Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer J. Clin. Oncol. 27 2009 3611 3619